Economic evaluation of the prevention and management of systemic fungal infections in neutropenic patients.
Systemic fungal infections in neutropenic patients remain a clinical problem that is associated with morbidity and mortality. Continuing efforts are being made to develop improved (i.e., more effective or safe) drugs, and several new treatments have recently become available. These have increased the therapeutic options available to clinicians to address the problem of systemic fungal infections. Therapeutic choices are difficult when taking into account aspects of efficacy, safety and costs that are associated with the available alternatives. This review summarises the present status of health economic knowledge of the standard therapies that have been available for many years, and also reports on the most recent health economic evidence available for the newly developed treatment alternatives.
Moeremans
Karen
K
HEDM-IMSHealth, Crayerstraat 6, 1000 Brussels, Belgium. KMoeremans@be.imshealth.com
Annemans
Lieven
L
D000935:Antifungal Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D006801:Humans; D009181:Mycoses / Q000188:drug therapy / Q000191:economics / Q000517:prevention & control; D009503:Neutropenia / Q000150:complications*; D016032:Randomized Controlled Trials as Topic
D000935:Antifungal Agents